HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The methyl-CpG-binding domain 2 facilitates pulmonary fibrosis by orchestrating fibroblast to myofibroblast differentiation.

Abstract
Although DNA methylation has been recognised in the pathogenesis of idiopathic pulmonary fibrosis (IPF), the exact mechanisms are yet to be fully addressed. Herein, we demonstrate that lungs originated from IPF patients and mice after bleomycin (BLM)-induced pulmonary fibrosis are characterised by altered DNA methylation along with overexpression in myofibroblasts of methyl-CpG-binding domain 2 (MBD2), a reader responsible for interpreting DNA methylome-encoded information. Specifically, depletion of Mbd2 in fibroblasts or myofibroblasts protected mice from BLM-induced pulmonary fibrosis coupled with a significant reduction of fibroblast differentiation. Mechanistically, transforming growth factor (TGF)-β1 induced a positive feedback regulatory loop between TGF-β receptor I (TβRI), Smad3 and Mbd2, and erythroid differentiation regulator 1 (Erdr1). TGF-β1 induced fibroblasts to undergo a global DNA hypermethylation along with Mbd2 overexpression in a TβRI/Smad3 dependent manner, and Mbd2 selectively bound to the methylated CpG DNA within the Erdr1 promoter to repress its expression, through which it enhanced TGF-β/Smad signalling to promote differentiation of fibroblast into myofibroblast and exacerbate pulmonary fibrosis. Therefore, enhancing Erdr1 expression strikingly reversed established pulmonary fibrosis. Collectively, our data support that strategies aimed at silencing Mbd2 or increasing Erdr1 could be viable therapeutic approaches for prevention and treatment of pulmonary fibrosis in clinical settings.
AuthorsYi Wang, Lei Zhang, Teng Huang, Guo-Rao Wu, Qing Zhou, Fa-Xi Wang, Long-Min Chen, Fei Sun, Yongman Lv, Fei Xiong, Shu Zhang, Qilin Yu, Ping Yang, Weikuan Gu, Yongjian Xu, Jianping Zhao, Huilan Zhang, Weining Xiong, Cong-Yi Wang
JournalThe European respiratory journal (Eur Respir J) Vol. 60 Issue 3 (09 2022) ISSN: 1399-3003 [Electronic] England
PMID35086828 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright ©The authors 2022.
Chemical References
  • Receptors, Transforming Growth Factor beta
  • Transforming Growth Factor beta
  • Transforming Growth Factor beta1
  • Bleomycin
  • Transforming Growth Factors
  • DNA
Topics
  • Animals
  • Bleomycin (adverse effects)
  • Cell Differentiation
  • DNA
  • Fibroblasts (metabolism)
  • Idiopathic Pulmonary Fibrosis (pathology)
  • Lung (pathology)
  • Mice
  • Myofibroblasts (metabolism)
  • Receptors, Transforming Growth Factor beta (metabolism)
  • Transforming Growth Factor beta (metabolism)
  • Transforming Growth Factor beta1 (metabolism)
  • Transforming Growth Factors (adverse effects, metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: